Daniel Vitt, Immunic Therapeutics CEO
April 6, 2023 11:12 AM EDT
R&D

Im­mu­nic touts pos­i­tive da­ta in main­te­nance phase of failed PhII tri­al, pulls back on an­oth­er as­set

Paul Schloesser

Associate Editor

A New York biotech is now say­ing it has pos­i­tive main­te­nance da­ta from a Phase II tri­al, more than 10 months af­ter re­port­ing the orig­i­nal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times